Evaluation of the Effectiveness of the Belatacept (Nulojix) Patient Alert Cards in Patients Following Renal Transplantation in European Economic Area Countries
Phase of Trial: Phase IV
Latest Information Update: 21 Jun 2017
At a glance
- Drugs Belatacept (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 14 Jun 2017 Status changed from recruiting to completed.
- 13 Apr 2017 Planned End Date changed from 1 Jan 2017 to 30 Jun 2017.
- 13 Apr 2017 Planned primary completion date changed from 1 Oct 2016 to 30 Jun 2017.